VEGFA and age-related macular degeneration: Furthermore, brolucizumab (Sharma et al., 2021; Bulirsch et al., 2022) is a novel monoclonal antibody anti-VEGF drug for the treatment of n-AMD, with more research significance in its efficacy and safety than other anti-VEGF drugs (Sharma et al., 2021; Tamashiro et al., 2022; Agostini et al., 2020; Bulirsch et al., 2022).